Tirzepatide acts as a dual GLP-1 and GIP receptor agonist examined in incretin-based metabolic research. Human clinical studies report measurable reductions in HbA1c levels, body-weight–related endpoints, and improved insulin sensitivity markers compared to placebo-controlled groups. Supplied as a research peptide in a sterile glass vial for laboratory research use only.
Price range: $40.00 through $205.00
Tirzepatide is supplied as a research peptide in a sealed sterile glass vial.
Each batch undergoes analytical verification to confirm molecular identity and purity prior to release.
In scientific literature, Tirzepatide acts as a dual GLP-1 and GIP receptor agonist examined in incretin-based metabolic research.
Human clinical studies report measurable reductions in HbA1c levels, body-weight–related endpoints, and improved insulin sensitivity markers compared to placebo-controlled groups.
Investigated in structured metabolic research settings involving type-2 diabetes and obesity biomarker evaluation.
All reported findings originate from structured laboratory or regulated human clinical research environments.
These outcomes reflect observed biomarker and pathway changes under controlled conditions and are not established therapeutic claims.
This product is provided exclusively for scientific research and laboratory development purposes.
It is not approved for human consumption, medical treatment, or diagnostic application.
Researchers are responsible for ensuring compliance with applicable laws and regulatory standards governing acquisition and use.
